NASDAQ$BEAM
Beam Therapeutics Inc. · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Reported business and pipeline updates and financial results for the third quarter of 2021.
Beam Therapeutics announced the FDA clearance of its IND application for BEAM-101, initiated IND-enabling studies for BEAM-102, and continued progress on BEAM-201. They also executed a non-exclusive option and license agreement with Sana Biotechnology for Cas12b.
- FDA cleared IND application for BEAM-101 for sickle cell disease treatment.
- Initiated IND-enabling studies for BEAM-102 for sickle cell disease treatment.
- Continued progress on BEAM-201 for T-cell acute lymphoblastic leukemia treatment.
- Executed non-exclusive option and license agreement with Sana Biotechnology for Cas12b.
Headline financials
Revenue & EPS history
Beam Therapeutics · Revenue · Quarterly
$763K
Revenue by segment
Beam Therapeutics · $6K total across 1 segment · Q2 2021
- License & collaboration revenue$6K—100.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+1.1%
Avg return
Earnings day
-0.1%
Avg return
5 days after
+3.6%
Avg return
30 days after
56%
14 / 25 earnings
Positive
+21.8%
Q4 2023
Best reaction
-11.1%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.8% | -2.4% | -9.3% | |
| Q4 2025 | +14.1% | +0.5% | -16.6% | |
| Q3 2025 | -6.4% | -8.4% | +19.2% | |
| Q1 2025 | +3.9% | -0.2% | -1.1% | |
| Q4 2024 | -3.1% | -14.5% | -27.9% | |
| Q3 2024 | +9.3% | +11.1% | +3.9% | |
| Q2 2024 | -4.5% | -4.5% | -5.6% | |
| Q1 2024 | -2.4% | -6.7% | +5.7% | |
| Q4 2023 | +21.8% | +11.3% | -7.7% | |
| Q3 2023 | -11.1% | -12.2% | +5.6% | |
| Q2 2023 | +2.2% | +0.0% | -1.5% | |
| Q1 2023 | +1.9% | +4.3% | -6.7% | |
| Q4 2022 | -1.3% | +0.3% | -22.7% | |
| Q3 2022 | -10.3% | +19.0% | +3.0% | |
| Q2 2022 | +3.2% | +8.5% | -10.4% | |
| Q1 2022 | +0.3% | -0.6% | +12.6% | |
| Q4 2021 | -1.7% | -14.3% | -20.5% | |
| Q3 2021 | +9.1% | +2.9% | -11.4% | |
| Q2 2021 | +1.0% | -5.6% | +1.0% | |
| Q1 2021 | +4.3% | +12.2% | +37.1% | |
| Q4 2020 | -4.4% | -5.6% | -22.3% | |
| Q3 2020 | +2.5% | -1.4% | +109.9% | |
| Q2 2020 | -5.1% | -3.5% | +8.6% | |
| Q1 2020 | +3.3% | +3.4% | +23.1% | |
| Q4 2019 | +3.3% | +3.4% | +23.1% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro